Literature DB >> 6896298

Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.

G Perez Manga, P Madrigal Alonso, H Alburquerque Carbuccia.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896298     DOI: 10.1007/bf00254557

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  4 in total

1.  Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.

Authors:  D L Ahmann; H F Bisel; R T Eagan; J H Edmonson; R G Hahn
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

2.  An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.

Authors:  J Rubin; D A Decker; D L Ahmann; R T Eagan; J N Ingle; R G Hahn
Journal:  Oncology       Date:  1980       Impact factor: 2.935

3.  Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.

Authors:  S E Jones; B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

Review 4.  Etoposide (VP-16-213).

Authors:  B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

  4 in total
  2 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Phase II study with etoposide in previously untreated advanced breast cancer.

Authors:  H E Wander; W Rauschning; D Meyer; W Achterrath; G A Nagel
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.